Evidence map›Paper›PMID 41234517›Full record

ArticleFrontiers in cellular and infection microbiology2025

Siglec-9 acts as an immune checkpoint marker on MDSCs in brucella infection.

Huidong Shi, Xinxin Qi, Kaiyu Shang, Tingting Tian, Jianbing Ding, Mingzhe Li, Ruixue Xu, Fuling Pu, Junyu Kuang, Yuejie Zhu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. OralFrontiers in microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huidong Shi *State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Xinxin Qi *Department of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Kaiyu ShangState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Tingting TianState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Jianbing DingState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Mingzhe LiDepartment of Medical Laboratory Technology, School of Medicine, Xinjiang Medical University, Urumqi, China.
Ruixue XuDepartment of Medical Laboratory Technology, School of Medicine, Xinjiang Medical University, Urumqi, China.
Fuling PuDepartment of Medical Laboratory Technology, School of Medicine, Xinjiang Medical University, Urumqi, China.
Junyu KuangDepartment of Medical Laboratory Technology, School of Medicine, Xinjiang Medical University, Urumqi, China.
Yuejie ZhuReproductive Medicine Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Fengbo ZhangState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Brucellosis is a zoonotic disease that is widely prevalent in the Xinjiang region of China. Once it progresses to a chronic stage, it can lead to significant complications. Immune checkpoints markers on Myeloid-derived suppressor cells (MDSCs) may lead to the chronic stage of the disease. This study analyzed the changes in MDSCs, immune checkpoints markers and cytokines in the patients with acute and chronic Brucella infections and after antibiotic treatment, to explore their roles and provide new ideas for future clinical treatment. Methods: A total of 37 patients with acute brucellosis infection (ABI) and 46 patients with chronic brucellosis infection (CBI) and 43 healthy controls (HC) subjects were enrolled. Flow cytometry was used to detect the expression of MDSCs, Siglec-9 Results: Our study found that the levels of MDSCs in the patients significantly increased, with CBI patients exhibiting higher levels than ABI patients. The cytokines showed varying degrees of elevation. Furthermore, after antibiotic treatment, the levels of MDSCs, Siglec-9 Conclusion: MDSCs are increased in both ABI and CBI. Siglec-9 acts as an immune checkpoint on MDSCs in patients with ineffective treatment responses. Therefore, Siglec-9 represents a potential prognostic marker for Brucella infection. Ongoing research on prognostic markers of brucellosis is promising, and further clinical studies are warranted to validate these findings.

Indexed as

BrucellosisImmune Checkpoint ProteinsMyeloid-Derived Suppressor CellsSialic Acid Binding Immunoglobulin-like LectinsAdultAnti-Bacterial AgentsBiomarkersBrucellaChinaCytokinesFemaleHepatitis A Virus Cellular Receptor 2HumansInterleukin-6MaleMiddle AgedAnti-Bacterial AgentsBiomarkersCytokinesHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2Immune Checkpoint ProteinsInterleukin-6PDCD1 protein, humanProgrammed Cell Death 1 ReceptorSialic Acid Binding Immunoglobulin-like LectinsBrucellosisCytokinesMDSCsPD-1Siglec-9Tim-3

Identifiers

PMID41234517
PMCPMC12605041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.